Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Chief Business Officer | January 16, 2024 | January 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RECURSION PHARMACEUTICALS, INC.
Report date January 16, 2024 · Filed January 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 136,748 |
Ending reported balance
After 2024-01-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-01-16 · Exercise / conversion · Acquired 18,000 · Balance 154,748 F1: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Row 2 · 2024-01-16 · Sale · Disposed 18,000 · Balance 136,748 F1: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.22 · Expires 2030-03-03 | Direct | 361,469 |
Reported balance
After 2024-01-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-16 · Exercise / conversion · Disposed 18,000 · Balance 361,469 F1: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. F3: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2033-02-01 | Direct | 212,507 |
Reported balance
Holding disclosure · report date 2024-01-16 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 212,507 F2: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 80,450 |
Reported balance
Holding disclosure · report date 2024-01-16 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 80,450 F4: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 5,436 |
Reported balance
Holding disclosure · report date 2024-01-16 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 5,436 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023.
F2: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F3: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date.
F4: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 16, 2024 Filed Jan 18, 2024 23:39 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-24-001870 · doc4.xml · derivative · entry 4 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 361,469 Underlying: Class A Common Stock · 18,000 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 23:39 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 18,000 | $10.93 | $196,740.00 |
DisclosureSEC source: 0001209191-24-001870 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,748 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 23:39 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 18,000 | $2.22 | $39,960.00 |
DisclosureSEC source: 0001209191-24-001870 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:22 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-059254 · doc4.xml · derivative · entry 4 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 379,469 Underlying: Class A Common Stock · 18,000 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:22 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 18,000 | $9.60 | $172,800.00 |
DisclosureSEC source: 0001209191-23-059254 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,748 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:22 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 18,000 | $2.22 | $39,960.00 |
DisclosureSEC source: 0001209191-23-059254 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 22:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-055843 · doc4.xml · derivative · entry 5 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 397,469 Underlying: Class A Common Stock · 18,000 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. F4 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 22:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 3,603 | $7.18 | $25,869.54 |
DisclosureSEC source: 0001209191-23-055843 · doc4.xml · nonDerivative · entry 3 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,748 F2 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 22:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 18,000 | $6.51 | $117,180.00 |
DisclosureSEC source: 0001209191-23-055843 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,351 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 22:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 18,000 | $2.22 | $39,960.00 |
DisclosureSEC source: 0001209191-23-055843 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 21:34 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-053107 · doc4.xml · derivative · entry 4 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 415,469 Underlying: Class A Common Stock · 18,000 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 21:34 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 18,000 | $6.30 | $113,400.00 |
DisclosureSEC source: 0001209191-23-053107 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,351 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 21:34 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 18,000 | $2.22 | $39,960.00 |
DisclosureSEC source: 0001209191-23-053107 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-050033 · doc4.xml · derivative · entry 4 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 433,469 Underlying: Class A Common Stock · 18,000 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 18,000 | $8.66 | $155,880.00 |
DisclosureSEC source: 0001209191-23-050033 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,351 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 18,000 | $2.22 | $39,960.00 |
DisclosureSEC source: 0001209191-23-050033 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 22:39 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-046424 · doc4.xml · derivative · entry 5 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 451,469 Underlying: Class A Common Stock · 18,000 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. F4 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 22:39 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 18,000 | $9.25 | $166,500.00 |
DisclosureSEC source: 0001209191-23-046424 · doc4.xml · nonDerivative · entry 3 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,351 F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 22:39 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 18,000 | $2.22 | $39,960.00 |
DisclosureSEC source: 0001209191-23-046424 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 22:39 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 3,603 | $9.19 | $33,111.57 |
DisclosureSEC source: 0001209191-23-046424 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,351 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| July 26, 2023 Filed Jul 27, 2023 22:31 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-043581 · doc4.xml · derivative · entry 7 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 469,469 Underlying: Class A Common Stock · 20,000 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| July 26, 2023 Filed Jul 27, 2023 22:31 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,000 | $14.41 | $288,200.00 |
DisclosureSEC source: 0001209191-23-043581 · doc4.xml · nonDerivative · entry 4 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,954 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| July 26, 2023 Filed Jul 27, 2023 22:31 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 20,000 | $2.22 | $44,400.00 |
DisclosureSEC source: 0001209191-23-043581 · doc4.xml · nonDerivative · entry 3 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 22:31 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-043581 · doc4.xml · derivative · entry 6 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 489,469 Underlying: Class A Common Stock · 20,000 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 22:31 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 20,000 | $14.30 | $286,000.00 |
DisclosureSEC source: 0001209191-23-043581 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,954 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 22:31 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 20,000 | $2.22 | $44,400.00 |
DisclosureSEC source: 0001209191-23-043581 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 23:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-042794 · doc4.xml · derivative · entry 7 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 509,469 Underlying: Class A Common Stock · 30,000 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 23:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 30,000 | $13.74 | $412,200.00 |
DisclosureSEC source: 0001209191-23-042794 · doc4.xml · nonDerivative · entry 4 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,954 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 23:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 30,000 | $2.22 | $66,600.00 |
DisclosureSEC source: 0001209191-23-042794 · doc4.xml · nonDerivative · entry 3 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 23:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-042794 · doc4.xml · derivative · entry 6 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 539,469 Underlying: Class A Common Stock · 30,000 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 23:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 30,000 | $11.72 | $351,600.00 |
DisclosureSEC source: 0001209191-23-042794 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,954 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 23:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 30,000 | $2.22 | $66,600.00 |
DisclosureSEC source: 0001209191-23-042794 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 22:56 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-038616 · doc4.xml · derivative · entry 7 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 569,469 Underlying: Class A Common Stock · 30,000 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023 F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 22:56 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 30,000 | $9.41 | $282,300.00 |
DisclosureSEC source: 0001209191-23-038616 · doc4.xml · nonDerivative · entry 4 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,954 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023 Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 22:56 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 30,000 | $2.22 | $66,600.00 |
DisclosureSEC source: 0001209191-23-038616 · doc4.xml · nonDerivative · entry 3 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023 Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 22:56 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-038616 · doc4.xml · derivative · entry 6 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 599,469 Underlying: Class A Common Stock · 30,000 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023 F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 22:56 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 30,000 | $9.67 | $290,100.00 |
DisclosureSEC source: 0001209191-23-038616 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,954 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023 Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 22:56 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 30,000 | $2.22 | $66,600.00 |
DisclosureSEC source: 0001209191-23-038616 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023 Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 22:29 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 17,865 | $8.93 | $159,534.45 |
DisclosureSEC source: 0001209191-23-034601 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,954 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:29 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 25,000 | $8.58 | $214,500.00 |
DisclosureSEC source: 0001209191-23-034601 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,819 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. F2 · balance_after: Includes 1,717 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on May 22, 2023. Read SEC document |
| May 15, 2023 Filed May 17, 2023 22:20 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 2,230 | $5.60 | $12,488.00 |
DisclosureSEC source: 0001209191-23-030380 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,102 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 22:13 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 1,768 | $8.42 | $14,886.56 |
DisclosureSEC source: 0001209191-23-010774 · doc4.xml · nonDerivative · entry 4 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,332 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:13 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,486 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-010774 · doc4.xml · derivative · entry 6 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 629,469 Underlying: Class A Common Stock · 7,486 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person F4 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:13 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 746 | $8.44 | $6,296.24 |
DisclosureSEC source: 0001209191-23-010774 · doc4.xml · nonDerivative · entry 3 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,100 F2 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:13 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 7,486 | $8.33 | $62,358.38 |
DisclosureSEC source: 0001209191-23-010774 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,846 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:13 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 7,486 | $2.22 | $16,618.92 |
DisclosureSEC source: 0001209191-23-010774 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:12 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 212,507 | $0.00 Strike: $8.55 | $0.00 |
DisclosureSEC source: 0001209191-23-007045 · doc4.xml · derivative · entry 4 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,507 Underlying: Class A Common Stock · 212,507 shares Expires 2033-02-01 F5 · derivative.exercise_date: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:12 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 2,994 | $8.55 | $25,598.70 |
DisclosureSEC source: 0001209191-23-007045 · doc4.xml · nonDerivative · entry 3 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,846 F4 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:12 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 10,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007045 · doc4.xml · nonDerivative · entry 2 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,840 F3 · kind: This RSU vested immediately upon the grant date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:12 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 106,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007045 · doc4.xml · nonDerivative · entry 1 Virani Shafique · CIK 0001856081 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,003 F1 · kind: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2023 and every three months thereafter. F2 · balance_after: Includes 2,590 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.